International: +1-347-960-6455
Proctitis Therapeutics - Pipeline Analysis 2018

Proctitis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10035 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Gastroenterology
Select License Type

Proctitis is characterized by the inflamed lining tissue of the inner rectum due to several medical conditions. The common causes of proctitis are sexually-transmitted infections (STIs), inflammatory bowel diseases (ulcerative colitis and Crohn’s disease), anal trauma, rectal infections, and radiation therapy for ovarian, anal, rectal, or prostate cancer. Tenesmus; pain in rectum, anus, and abdominal region; bleeding from rectum; watery diarrhea; mucus discharge from rectum; and loose stools are some of the symptoms of proctitis. The standard treatments available for proctitis are medications which includes anti-inflammatory drugs, antibiotics, antifungals, and immunosuppressants. Some of the major companies operating in the proctitis pipeline arena includes Synedgen Inc. and Innovation Pharmaceuticals Inc.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.